[{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Endeavor Biomedicines \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Omega Funds"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Series B Financing","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Ally Bridge Group","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Ally Bridge Group"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"xCures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Taladegib","moa":"Hedgehog signaling pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ xCures","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ xCures"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Taladegib","moa":"Hedgehog pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ AyurMaya"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Taladegib","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Taladegib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 19, 2024

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Endeavor will use the financing proceeds to advance the clinical development of ENV-101, its lead candidate for the treatment of idiopathic pulmonary fibrosis.

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 24, 2024

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : AyurMaya

                          Deal Size : $132.5 million

                          Deal Type : Series C Financing

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ENV-101 (taladegib) is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway. It is being evaluated in phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis.

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 24, 2024

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ENV-101 (taladegib) is a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a critical role in idiopathic pulmonary fibrosis disease pathology.

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 06, 2023

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial for ENV-101 (taladegib). The xCures platform also enables patients to find more suitable treatment options if they are ine...

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 31, 2022

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : xCures

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ENV-101 (taladegib), an orally available small molecule inhibitor of the Hedgehog signaling pathway, has already demonstrated preliminary clinical efficacy and safety in nearly 200 subjects enrolled across six completed studies.

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 25, 2022

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Proceeds will support the Endeavor’s pipeline, including ENV-101 (taladegib), a small molecule inhibitor of PTCH1 receptor, for the treatment of cancer and idiopathic pulmonary fibrosis and ENV-201, a small molecule inhibitor of ULK1/2 for the treatmen...

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 07, 2022

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Ally Bridge Group

                          Deal Size : $101.0 million

                          Deal Type : Series B Financing

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.

                          Brand Name : ENV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 07, 2021

                          Lead Product(s) : Taladegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Omega Funds

                          Deal Size : $62.0 million

                          Deal Type : Series A Financing

                          blank